Announcing the Next President of the Edward P. Evans Foundation

Timothy A. Graubert, M.D.

I write today on behalf of the Board of Trustees of the Edward P. Evans Foundation. It is our great pleasure to announce the appointment of Timothy A. Graubert, MD, as the second president of the Foundation. Well-known to the myelodysplastic syndrome (MDS) community, Dr. Graubert is a major leader in MDS research investigating the genetic and biologic bases of the disease to drive future targeted therapy. He is a Professor of Medicine, Harvard Medical School, and currently serves as the Director of the Hematologic Malignancy Program at Massachusetts General Hospital where he is also an active clinician caring for MDS patients. We are delighted to announce that he will join the Foundation as President in January 2025.

The Edward P. Evans Foundation would not be where it is today were it not for the visionary leadership, unwavering dedication, and tireless efforts of Michael Lewis, Ph.D., who has led the Foundation for the past decade. His commitment to our mission has been an inspiration. Michael has distributed approximately $150M towards basic, translational, and clinical research through an annual competitive grants program, funding the most promising investigators. He has transformed the Foundation to be the premier funder of MDS research, supported the career trajectory of young faculty, spearheaded the establishment of five endowed Edward P. Evans Centers for Myelodysplastic Syndromes, and coordinated an annual MDS summit at which the innovative research of EvansMDS-funded investigators is presented and discussed.  His legacy will continue to shape the future of this organization.

As Michael transitions the leadership of the Edward P. Evans Foundation to Tim, we are delighted to announce that he will join the Board of Trustees. He will continue to share his wisdom and experience to benefit the Foundation in this new role. We look forward to his ongoing contributions, confident that the Foundation will continue to thrive.

On behalf of the Board of Trustees, we thank Michael for his extraordinary leadership and congratulate him on this well-deserved transition. We welcome Tim as President, and we look forward to the next decade of transformative and impactful research that will lead to a cure for MDS.

With deepest appreciation and warm regards,

Barbara E. Bierer, M.D.

Robert S. Evans
William S. Farish, Jr.
Benjamin Polak, Ph.D.
James L. L. Tullis